tetano
Editor, Senior Moderator
Eur Heart J
. 2024 Jul 12:ehae335.
doi: 10.1093/eurheartj/ehae335. Online ahead of print. Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study
You-Jung Choi[SUP] 1 2 [/SUP], Jaehyun Lim[SUP] 3 [/SUP], Sungho Bea[SUP] 4 5 [/SUP], Jieun Lee[SUP] 1 [/SUP], Jah Yeon Choi[SUP] 1 [/SUP], Seung Young Rho[SUP] 1 [/SUP], Dae-In Lee[SUP] 1 [/SUP], Jin Oh Na[SUP] 1 [/SUP], Hyung-Kwan Kim[SUP] 3 [/SUP]
Affiliations
Background and aims: Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL.
Methods: This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0-21 days following COVID-19 vaccination.
Results: The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77-1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39-2.54) following vaccination.
Conclusions: In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination.
Keywords: Anticoagulant therapy; Atrial fibrillation; Atrial flutter; COVID-19 vaccine; Modified self-controlled case-series; Thrombo-embolic risk.
. 2024 Jul 12:ehae335.
doi: 10.1093/eurheartj/ehae335. Online ahead of print. Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study
You-Jung Choi[SUP] 1 2 [/SUP], Jaehyun Lim[SUP] 3 [/SUP], Sungho Bea[SUP] 4 5 [/SUP], Jieun Lee[SUP] 1 [/SUP], Jah Yeon Choi[SUP] 1 [/SUP], Seung Young Rho[SUP] 1 [/SUP], Dae-In Lee[SUP] 1 [/SUP], Jin Oh Na[SUP] 1 [/SUP], Hyung-Kwan Kim[SUP] 3 [/SUP]
Affiliations
- PMID: 38993069
- DOI: 10.1093/eurheartj/ehae335
Background and aims: Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL.
Methods: This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0-21 days following COVID-19 vaccination.
Results: The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77-1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39-2.54) following vaccination.
Conclusions: In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination.
Keywords: Anticoagulant therapy; Atrial fibrillation; Atrial flutter; COVID-19 vaccine; Modified self-controlled case-series; Thrombo-embolic risk.